RT Journal Article
SR Electronic
T1 Organizational impact of an ID NOW™ COVID-19 point-of-care testing for SARS-CoV2 detection in a maternity ward
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.29.22279161
DO 10.1101/2022.08.29.22279161
A1 Van, Jean-Claude Nguyen
A1 Pilmis, Benoît
A1 Khaterchi, Amir
A1 Billuart, Olivier
A1 De Ponfilly, Gauthier Péan
A1 Monnier, Alban Le
A1 Azria, Elie
A1 Mizrahi, Assaf
YR 2022
UL http://medrxiv.org/content/early/2022/08/30/2022.08.29.22279161.abstract
AB Background SARS-CoV-2 has been responsible for more than 550 million cases of COVID-19 worldwide. RT-PCR is considered the “gold standard” for the diagnosis of patients suspected of having COVID-19. During the heightened waves of the pandemic, more rapid tests have been required. Point-of-care tests (POCT) for COVID-19 include antigen tests, serological tests, and other molecular-based platforms. The ID NOW™ COVID-19 assay (Abbott) performs an isothermal gene amplification of a target encoding the RNA-dependent RNA polymerase of SARSCoV-2. The main objective of this study was to evaluate the organizational impact following the implementation of a POC testing platform ID NOW™ in a maternity ward.Materials and Methods This retrospective study included pregnant women admitted for Groupe Hospitalier Paris Saint-Joseph Paris. The study was conducted over 2 periods lasting 6 months each. The first period (P1) corresponded to the 2nd wave in France (July to December 2020) whereas the second (P2) period focused on the 3rd wave (February to July 2021). During P1, viral detection was performed by RT-PCR at the hospital’s laboratory. During P2, it was performed with the ID NOW™ COVID-19 test directly in the delivery room by nursing staff after training and certification. Our primary endpoint was the length of time in the birth room from admission to discharge in the postpartum period.Results 2447 pregnant women were included, 1053 during P1 and 1394 during P2. The median age, percentage of singleton pregnancies, mean gestational age, percentage of nulliparous individuals, percentage of vaginal deliveries, and COVID19 positivity rate were comparable between the two periods. During P2, the length of stay in the delivery room was significantly shorter than during P1 (17.9 vs 14.7 hours, p<0.001).Conclusion Analysis of the data from this study following the implementation of the ID NOW™ POCT in the maternity ward indicates a significant decrease in the length of stay in the birth room. This outcome needs to be confirmed in a multicenter cohort, in particular to precise the specific impact of COVID-19 care on delays.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialID DELOCOVIDMATER NCT05175716Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study followed the guidelines of the Standards for Reporting of Diagnostic Accuracy studies (STARD) and was previously approved by the clinical ethics committee of Saint Joseph hospital called "Groupe Ethique Recherche Medicale" which issued a favorable ethical opinion and registered in the single protocol DELOCOVIDMATER NCT05175716 of clinical trial.gov (https://clinicaltrials.gov/ct2/show/NCT05175716). Informed oral consent for participation was obtained from each participant, in accordance with French law.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript